Virus-Like Particle Vaccines: Advantages and Challenges

Development of Vaccines: From Discovery to Clinical Testing

Volumn , Issue , 2011, Pages 97-124

  Ross, Ted M ^a   Bhardwaj, Nitin ^a   Eugene, Hermancia S ^a   Giles, Brendan M ^a   McBurney, Sean P ^a   Rossi, Shannan L ^a   Schneider Ohrum, Kirsten ^a   Tang, Xian Chun ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Flaviviruses, of family flaviviridae medical importance, in yellow fever, japanese encephalitis, dengue, tick borne encephalitis and west nile viruses; Norovirus (or norwalk virus) member of caliciviridae, and nonbacterial gastroenteritis; Vaccine platforms, virus like particle vaccines challenges, disease and infectious agents

Indexed keywords

EID: 84886185369     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118023648.ch4     Document Type: Chapter

References (137)

1. Ellenberger D, Li B, Smith J, Yi H, Folks T, et al. Optimization of a multi-gene HIV-1 recombinant subtype CRF02_AG DNA vaccine for expression of multiple immunogenic forms. Virology 2004;319:118-130.
2. Johnson JE and Chiu W. Structures of virus and virus-like particles. Curr. Opin. Struct. Biol . 2000;10:229-235.
3. Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD., et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 2008;3:e1501.
4. Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007;25:3871-3878.
5. Kovacsovics-Bankowski M and Rock KL. Presentation of exogenous antigens by macrophages: Analysis of major histocompatibility complex class I and II presentation and regulation by cytokines. Eur. J. Immunol. 1994;24:2421-2428.
6. McBurney SP, Young KR, and Ross TM. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology 2007;358:334-346.
7. Bessa J, Schmitz N, Hinton HJ, Schwarz K, Jegerlehner A, et al. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: Implications for vaccine design. Eur. J. Immunol. 2008;38:114-126.
8. McBurney SP, Young KR, Nwaigwe CI, Soloff AC, Cole KS, et al. Lentivirus-like particles without reverse transcriptase elicit efficient immune responses. Curr. HIV Res. 2006;4:475-484.
9. Grgacic EV and Anderson DA. Virus-like particles: Passport to immune recognition. Methods 2006;40:60-65.
10. Ravanfar P, Satyaprakash A, Creed R, and Mendoza N. Existing antiviral vaccines. Dermatol. Ther. 2009;22:110-128.
11. Jennings GT and Bachmann MF. The coming of age of virus-like particle vaccines. Biol Chem. 2008;389:521-536.
12. Takeuchi O and Akira S. Innate immunity to virus infection. Immunol. Rev. 2009;227:75-86.
13. Akira S. TLR signaling. Curr. Top. Microbiol. Immunol. 2006;311:1-16.
14. Jegerlehner A, Maurer P, Bessa J, Hinton HJ, Kopf M, et al. TLR9 signaling in B cells determines class switch recombination to IgG2a. J. Immunol. 2007;178:2415-2420.
15. Yan M, Peng J, Jabbar IA, Liu X, Filgueira L, et al. Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake, both cells cross-prime T cells. Virology 2004;324:297-310.
16. FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Diseases in Females Caused by Human Papillomavirus Rapid Approval Marks Major Advancement in Public Health. 2006 [cited 6/26/09]; Available from: http://www.fda.gov/News-Events/Newsroom/PressAnnouncements/2006/ucm108666.htm.
17. Howley PM and Lowy DR, Papillomavirus and their replication. In: Fields Virology, 4th ed. Lippincott Williams and Wilkins, Philadelphia, 2001, pp. 2179-2230.
18. Lowy DR and Howley PM. Papillomaviruses. In: Fields Virology, 4th ed. Lippincott Williams and Wilkins, Philadelphia, 2001, pp. 2231-2264.
19. Wang K-L. Human papillomavirus and vaccination in cervical cancer. Taiwan J. Obst. Gynecol. 2007;46:352-362.
20. Parkin DM and Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24:S11-S25.
21. Schwarz TF and Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: Improving upon nature. Gynecol. Oncol. 2008;110:S1-S10.
22. Stanley M, Lowy DR, and Frazer I. Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. Vaccine 2006;24:S106-S113.
23. Christensen ND, Reed CA, Cladel NM, Han R, and Kreider JW. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J. Virol . 1996;70:960-965.
24. Day PM, Thompson CD, Buck CB, Pang Y-YS, Lowy DR, et al. Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J. Virol . 2007;81:8784-8792.
25. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Nat. Acad. Sci . 1995;92:11553-11557.
26. Olcese V, Chen Y, Schlegel R, and Yuan H. Characterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitope. BMC Microbiol . 2004; 4:29.
27. Chen XS, Garcea RL, Goldberg I, Casini G, and Harrison SC. Structure of small viruslike particles assembled from the L1 protein of human papillomavirus 16. Mol. Cell 2000;5:557-567.
28. Kirnbauer R, Booy F, Cheng N, Lowy DR, and Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Nat. Acad. Sci . 1992;89:12180-12184.
29. Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, et al. Immunological analyses of human papillomavirus capsids. Vaccine 2001;19:1783-1793.
30. Inglis S, Shaw A, and Koenig S. Chapter 11: HPV vaccines: Commercial research & development. Vaccine 2006;24:S99-S105.
31. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-2170.
32. Schiller JT, Castellsagué X, Villa LL, and Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008;26:K53-K61.
33. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 2007;356:1928-1943.
34. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-871.
35. UNAIDS. 2007 AIDS epidemic update. 2008 [cited April 22, 2008]; available from: http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/2007/-default.asp.
36. Young KR, McBurney SP, Karkhanis LU, and Ross TM. Virus-like particles: Designing an effective AIDS vaccine. Methods 2006;40:98-117.
37. Girard MP, Osmanov SK, and Kieny MP. A review of vaccine research and development: The human immunodeficiency virus (HIV). Vaccine 2006;24:4062-4081.
38. Linh X. Doan ML, Chen C, Yao Q. Virus-like particles as HIV-1 vaccines. Rev. Med. Virol . 2005;75-88.
39. Ludwig C and Wagner R. Virus-like particles-universal molecular toolboxes. Curr. Opin. Biotech. 2007;18:537-545.
40. Lehner T. Innate and adaptive mucosal immunity in protection against HIV infection. Vaccine 2003;21(Suppl 2): S68-76.
41. Letvin NL. Progress toward an HIV vaccine. Annu. Rev. Med. 2005;56:213-223.
42. Montefiori DC, Safrit JT, Lydy SL, Barry AP, Bilska M, et al. Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. J. Virol . 2001;75:5879-5890.
43. Smith JM, Amara RR, Campbell D, Xu Y, Patel M, et al. DNA/MVA vaccine for HIV type 1: Effects of codon-optimization and the expression of aggregates or viruslike particles on the immunogenicity of the DNA prime. AIDS Res. Hum. Retroviruses 2004;20:1335-1347.
44. Young KR, Smith JM, and Ross TM. Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle. Virology 2004;327:262-272.
45. Tsunetsugu-Yokota Y, Morikawa Y, Isogai M, Kawana-Tachikawa A, Odawara T, et al. Yeast-derived human immunodeficiency virus type 1 p55gag virus-like particles activate dendritic cells (DCs) and induce perforin expression in Gag-specific CD8+ T cells by cross-presentation of DCs. J. Virol . 2003;77:10250-10259.
46. Deml L, Speth C, Dierich MP, Wolf H, and Wagner R. Recombinant HIV-1 Pr55gag virus-like particles: Potent stimulators of innate and acquired immune responses. Mol. Immunol. 2005;42:259-277.
47. Paliard X, Liu Y, Wagner R, Wolf H, Baenziger J, et al. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in Rhesus macaques. AIDS Res. Hum. Retroviruses. 2000;16:273-282.
48. Gheysen D, Jacobs E, de Foresta F, Thiriart C, Francotte M, et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 1989;59:103-112.
49. Royer M, Hong SS, Gay B, Cerutti M, and Boulanger P. Expression and extracellular release of human immunodeficiency virus type 1 Gag precursors by recombinant baculovirus-infected cells. J. Virol. 1992;66:3230-3235.
50. Shioda T and Shibuta H. Production of human immunodeficiency virus (HIV)-like particles from cells infected with recombinant vaccinia viruses carrying the gag gene of HIV. Virology. 1990;175:139-148.
51. Sakuragi S, Goto T, Sano K, and Morikawa Y. HIV type 1 Gag virus-like particle budding from spheroplasts of Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U.S.A. 2002;99:7956-7961.
52. Wagner R, Deml L, Schirmbeck R, Niedrig M, Reimann J, and Wolf H. Construction, expression and immunogenicity of chimeric HIV-1 virus-like particles. Virology. 1996;220:128-140.
53. Speth C, Bredl S, Hagleitner M, Wild J, Dierich M, et al. Human immunodeficiency virus type-1 (HIV-1) Pr55gag virus-like particles are potent activators of human monocytes. Virology 2008;382:46-58.
54. Buonaguro L, Tornesello ML, Tagliamonte M, Gallo RC, Wang LX, et al. Baculovirusderived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J. Virol . 2006;80:9134-9143.
55. Adams SE, Dawson KM, Gull K, Kingsman SM, and Kingsman AJ. The expression of hybrid HIV:Ty virus-like particles in yeast. Nature 1987;329:68-70.
56. Thomson MM, Perez-Alvarez L, and Najera R. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect. Dis. 2002;2:461-471.
57. McBurney SP and Ross TM. Developing broadly reactive HIV-1/AIDS vaccines: A review of polyvalent and centralized HIV-1 vaccines. Curr. Pharm. Des. 2007;13:1957-1964.
58. McBurney SP and Ross TM. Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines. Vaccine 2009;27:4337-4349.
59. Yao Q, Bu Z, Vzorov A, Yang C, and Compans RW. Virus-like particle and DNA-based candidate AIDS vaccines. Vaccine 2003;21:638-643.
60. Kang SM, Guo L, Yao Q, Skountzou I, and Compans RW. Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens. J. Virol . 2004;78:9624-9632.
61. Wagner R, Fließbach H, Wanner G, Motz M, Niedrig M, et al. Studies on processing, particle formation, and immunogenicity of the HIV-1gag gene product: A possible component of a HIV vaccine. Arch. Virol . 1992;127:117-137.
62. Brand D, Mallet F, Truong C, Roingeard P, Goudeau A, et al. A simple procedure to generate chimeric Pr55gag virus-like particles expressing the principal neutralization domain of human immunodeficiency virus type. J. Virol. Methods 1995;51:153-168.
63. Brand D, Srinivasan K, and Sodroski J. Determinants of human immunodeficiency virus type 1 entry in the CDR2 loop of the CD4 glycoprotein. J. Virol. 1995;69:166-171.
64. Griffiths JC, Harris SJ, Layton GT, Berrie EL, French TJ, et al. Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: Induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion. J. Virol. 1993;67:3191-3198.
65. Haffar O, Garrigues J, Travis B, Moran P, Zarling J, and Hu SL. Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J. Virol. 1990;64:2653-2659.
66. Haynes JR, Cao SX, Rovinski B, Sia C, James O, Dekaban GA, and Klein MH. Production of immunogenic HIV-1 virus like particles in stably engineered monkey cell lines. AIDS Res. Hum. Retroviruses. 1991;7:17-27.
67. Vzorov AN, Bukrinsky MI, Grigoriev VB, Tentsov YY, and Bukrinskaya AG. Highly immunogenic human immunodeficiency viruslike particles are produced by recombinant vaccinia virus-infected cells. AIDS Res. Hum. Retroviruses. 1991;7:29-36.
68. Krausslich HG, Ochsenbauer C, Traenckner AM, Mergener K, Facke M, Gelderblom HR, and Bosch V. Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase. Virology. 1993;192:605-617.
69. Rovinski B, Rodrigues L, Cao SX, Yao FL, McGuinness U, Sia C, Cates G, Zolla Pazner S, Karwowska S, and MatthewsT J. Induction of HIV type 1 neutralizing and env-CD4 blocking antibodies by immunization with genetically engineered HIV type 1-like particles containing unprocessed gp160 glycoproteins. AIDS Res. Hum. Retroviruses. 1995;11:1187-1195.
70. Tobin GJ, Nagashima K, and Gonda MA. Synthesis and assembly of chimeric human immunodeficiency virus gag pseudovirions, Intervirology. 1996;39:40-48.
71. Osterrieder N, Wagner R, Brandmuller C, Schmidt P, Wolf H, and Kaaden OR. Protection against EHV{-}1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB). Virology. 1995;208:500-510.
72. Garnier L, Ravallec M, Blanchard P, Bossy JP, Devauchelle G, Jestin A, and Cerutti M. Incorporation of pseudorabies virus gD into human immunodeficiency virus type 1 Gag particles produced in baculovirus-infected cells. J. Virol. 1995;69:4060-4068.
73. Deml L, Kratochwil G, Osterrieder N, Knuchel R, Wolf H, and Wagner R. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain. Virology. 1997;235:10-25.
74. Deml L, Schirmbeck R, Reimann J, Wolf H, and Wagner R. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Virology. 1997;235:26-39.
75. Luo L, Li Y, Cannon PM, Kim S, and Kang CY. Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies. Proc. Natl. Acad. Sci. U.S.A. 1992;89:10527-10531.
76. Fankhauser RL, Noel JS, Monroe SS, Ando T, and Glass RI. Molecular epidemiology of "Norwalk-like viruses" in outbreaks of gastroenteritis in the United States. J. Infect. Dis. 1998;178:1571-1578.
77. Patel MM, Hall AJ, Vinje J, and Parashar UD. Noroviruses: A comprehensive review. J. Clin. Virol . 2009;44:1-8.
78. Estes MK, Ball JM, Guerrero RA, Opekun AR, Gilger MA, et al. Norwalk virus vaccines: Challenges and progress. J. Infect. Dis. 2000;181(Suppl 2):S367-373.
79. Rockx B, De Wit M, Vennema H, Vinje J, De Bruin E, et al. Natural history of human calicivirus infection: A prospective cohort study. Clin. Infect. Dis. 2002;35:246-253.
80. Graham DY, Jiang X, Tanaka T, Opekun AR, Madore HP, et al. Norwalk virus infection of volunteers: New insights based on improved assays. J. Infect. Dis. 1994;170:34-43.
81. Karst SM, Wobus CE, Lay M, Davidson J, and Virgin HW. STAT1-dependent innate immunity to a Norwalk-like virus. Science 2003;299:1575-1578.
82. Wobus CE, Karst SM, Thackray LB, Chang KO, Sosnovtsev SV, et al. Replication of Norovirus in cell culture reveals a tropism for dendritic cells and macrophages. PLoS Biol . 2004;2:e432.
83. Green KY, Lew JF, Jiang X, Kapikian AZ, and Estes MK. Comparison of the reactivities of baculovirus-expressed recombinant Norwalk virus capsid antigen with those of the native Norwalk virus antigen in serologic assays and some epidemiologic observations. J. Clin. Microbiol . 1993;31:2185-2191.
84. Jiang X, Wang M, Graham DY, and Estes MK. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J. Virol . 1992;66:6527-6532.
85. Hutson AM, Atmar RL, Marcus DM, and Estes MK. Norwalk virus-like particle hemagglutination by binding to h histo-blood group antigens. J. Virol . 2003;77:405-415.
86. Lindesmith L, Moe C, Marionneau S, Ruvoen N, Jiang X, et al. Human susceptibility and resistance to Norwalk virus infection. Nat. Med. 2003;9:548-553.
87. Xia M, Farkas T, and Jiang X. Norovirus capsid protein expressed in yeast forms viruslike particles and stimulates systemic and mucosal immunity in mice following an oral administration of raw yeast extracts. J. Med. Virol . 2007;79:74-83.
88. Santi L, Batchelor L, Huang Z, Hjelm B, Kilbourne J, et al. An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine 2008;26:1846-1854.
89. Ball JM, Hardy ME, Atmar RL, Conner ME, and Estes MK. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J. Virol . 1998;72:1345-1353.
90. Ball JM, Graham DY, Opekun AR, Gilger MA, Guerrero RA, et al. Recombinant Norwalk virus-like particles given orally to volunteers: Phase I study. Gastroenterology 1999;117:40-48.
91. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, and Estes MK. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin. Immunol. 2003;108:241-247.
92. LoBue AD, Thompson JM, Lindesmith L, Johnston RE, and Baric RS. Alphavirusadjuvanted norovirus-like particle vaccines: Heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J. Virol . 2009;83:3212-3227.
93. Baric RS, Yount B, Lindesmith L, Harrington PR, Greene SR, et al. Expression and self-assembly of norwalk virus capsid protein from venezuelan equine encephalitis virus replicons. J. Virol . 2002;76:3023-3030.
94. Palese P and Shah M. Orthomyxoviridae: the viruses and their replication. In: Fields Virology. D Knipe and P Howley (Eds.). Lippincott, Williams and Wilkins, Philadelphia, 2007.
95. Obenauer JC, Denson J, Mehta P, Su X, and Mukatira S. Large-scale sequence analysis of avian influenza isolates. Science 2006;311:1576-1580.
96. Webster R, Bean W, Gorman O, Chambers T, and Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol. Rev. 1992;56:152-179.
97. Wright P, Neumann G, and Kawaoka Y. Orthomyxoviruses. In: Fields Virology, D. Knipe and P. Howley, Editors. 2007, Lippincott Williams & Wilkins, Phladelphia, 2007, pp. 1691-1740.
98. Maassab HF and DeBorde DC. Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine 1985;3:355-369.
99. Belshe RB. Current status of live attenuated influenza virus vaccine in the US. Virus Res. 2004;103:177-185.
100. Mena I, Vivo A, Perez E, and Portela A. Rescue of a synthetic chloramphenicol acetyltransferase RNA into influenza virus-like particles obtained from recombinant plasmids. J. Virol . 1996;70:5016-5024.
101. Gomez-Puertas P, Albo C, Perez-Pastrana E, Vivo A, and Portela A. Influenza virus matrix protein is the major driving force in virus budding. J. Virol . 2000;74:11538-11547.
102. Latham T and Galarza JM. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J. Virol . 2001;75:6154-6165.
103. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, et al. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005;23:5751-5759.
104. Quan FS, Huang C, Compans RW, and Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol 2007;81:3514-3524.
105. Crevar CJ and Ross TM. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virol. J . 2008;5:131.
106. Haynes JR, Dokken L, Wiley JA, Cawthon AG, Bigger J, et al. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 2009;27:530-541.
107. Perrone LA, Ahmad A, Veguilla V, Lu X, Smith G, et al. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J. Virol . 2009;83:5726-5734.
108. Abe T, Takahashi H, Hamazaki H, Miyano-Kurosaki N, Matsuura Y, et al. Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice. J. Immunol. 2003;171:1133-1139.
109. Kang SM, Yoo DG, Lipatov AS, Song JM, Davis CT, et al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS ONE 2009;4:e4667.
110. Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, et al. Pandemic potential of a strain of influenza A (H1N1): Early findings. Science 2009;324:1557-1561.
111. Peiris M, Yuen KY, Leung CW, Chan KH, Ip PLS, et al. Human infection with influenza H9N2. Lancet 1999;354:916-917.
112. Belser JA, Lu X, Maines TR, Smith C, Li Y, et al. Pathogenesis of avian influenza (H7) virus infection in mice and ferrets: Enhanced virulence of Eurasian H7N7 viruses isolated from humans. J. Virol . 2007;81:11139-11147.
113. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, et al. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005;23:5751-5759.
114. Pushko P, Tumpey TM, Van Hoeven N, Belser JA, Robinson R, et al. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine 2007;25:4283-4290.
115. Szecsi J, Gabriel G, Edfeldt G, Michelet M, Klenk Hans D, et al. DNA Vaccination with a single-plasmid construct coding for viruslike particles protects mice against infection with a highly pathogenic avian influenza A virus. J. Inf. Dis. 2009;200:181-190.
116. Vicente T, Peixoto C, Carrondo MJ, and Alves PM. Purification of recombinant baculoviruses for gene therapy using membrane processes. Gene Ther. 2009;16:766-775.
117. Fenner R. The classification and nomenclature of viruses. Intervirology 1975;6:1-12.
118. Daubney RJ, Hudson JR, and Garnham PC. Enzootic hepatitis or Rift Valley fever. An undescribed virus disease of sheep cattle and man from East Africa. J. Pathol. Bacter. 1931;34:545-579.
119. Coetzer JA. The pathology of Rift Valley fever. I. Lesions occurring in natural cases in new-born lambs. Onderstepoort J. Vet. Res. 1977;44:205-211.
120. Coetzer JA. The pathology of Rift Valley fever. II. Lesions occurring in field cases in adult cattle, calves and aborted foetuses. Onderstepoort J. Vet. Res. 1982;49:11-17.
121. Madani TA, Al-Mazrou YY, Al-Jeffri MH, Mishkhas AA, Al-Rabeah AM, et al. Rift Valley fever epidemic in Saudi Arabia: Epidemiological, clinical, and laboratory characteristics. Clin. Infect. Dis. 2003;37:1084-1092.
122. Kark JD, Aynor Y, and Peters CJ. A Rift Valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up. Am. J. Epidemiol. 1982;116:808-820.
123. Pittman PR, Liu CT, Cannon TL, Makuch RS, Mangiafico JA, et al. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: A 12-year experience. Vaccine 1999;18:181-189.
124. Smithburn KC. Rift Valley fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br. J. Exp. Pathol. 1949;30:1-16.
125. Metwally S. Foreign Animal Diseases, 7th ed. C Brown and A Torres (Eds.). Boca Publications Group, Boca Raton, FL, 2008, p. 8.
126. Botros B, Omar A, Elian K, Mohamed G, Soliman A, et al. Adverse response of nonindigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J. Med. Virol . 2006;78:787-791.
127. Coetzer JA and Barnard BJ. Hydrops amnii in sheep associated with hydranencephaly and arthrogryposis with wesselsbron disease and rift valley fever viruses as aetiological agents. Onderstepoort J. Vet. Res. 1977;44:119-126.
128. Lubroth J, Rweyemamu MM, Viljoen G, Diallo A, Dungu B, et al. Veterinary vaccines and their use in developing countries. Rev. Sci. Tech. 2007;26:179-201.
129. Muller R, Saluzzo JF, Lopez N, Dreier T, Turell M, et al. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am. J. Trop. Med. Hyg. 1995;53:405-411.
130. Caplen H, Peters CJ, and Bishop DH. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J. Gen. Virol . 1985;66(Pt 10): 2271-2277.
131. Morrill JC, Mebus CA, and Peters CJ. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am. J. Vet. Res. 1997;58:1104-1109.
132. Hunter P, Erasmus BJ, and Vorster JH. Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort J. Vet. Res. 2002;69:95-98.
133. Overby AK, Popov VL, Pettersson RF, and Neve EP. The cytoplasmic tails of Uukuniemi Virus (Bunyaviridae) G(N) and G(C) glycoproteins are important for intracellular targeting and the budding of virus-like particles. J. Virol . 2007;81:11381-11391.
134. Shi X, Kohl A, Leonard VH, Li P, McLees A, et al. Requirement of the N-terminal region of orthobunyavirus nonstructural protein NSm for virus assembly and morphogenesis. J. Virol . 2006;80:8089-8099.
135. Liu L, Celma CC, and Roy P. Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins. Virol. J . 2008;5:82.
136. Habjan M, Penski N, Wagner V, Spiegel M, Overby AK, et al. Efficient production of Rift Valley fever virus-like particles: The antiviral protein MxA can inhibit primary transcription of bunyaviruses. Virology 2009;385:400-408.
137. Naslund J, Lagerqvist N, Habjan M, Lundkvist A, Evander M, et al. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. Virology 2009;385:409-415.